FarhadRavandi-KashaniMD

Oncology • Houston, TX

Physician

Join to view full profile

Dr. Ravandi-Kashani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ravandi-Kashani's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161
Is this information wrong?

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1997 - 2000
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1994 - 1996
University of London Faculty of MedicineClass of 1987

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 1998 - 2025
OK State Medical License 2020 - 2021
IL State Medical License 2000 - 2005
American Board of Internal Medicine Hematology

Clinical Trials

SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia Start of enrollment: 2005 Dec 01
Terminated
Phase 1
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. Start of enrollment: 2006 Sep 28
Completed
Phase 2
Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) Start of enrollment: 2006 Aug 01
Completed
Phase 2, Phase 3
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia Start of enrollment: 2004 Jun 10
Recruiting
Phase 2
All-trans Retinoic Acid, and Arsenic +/- Idarubicin Start of enrollment: 2006 Dec 01
Completed
Phase 2
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) Start of enrollment: 2006 Dec 01
Completed
Phase 2
Alemtuzumab and Pentostatin In T-cell Neoplasms Start of enrollment: 2004 Sep 01
Terminated
Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Start of enrollment: 2007 Jul 11
Recruiting
Phase 2
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) Start of enrollment: 2007 Oct 01
Completed
Phase 1, Phase 2
Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies Start of enrollment: 2006 Aug 01
Completed
Phase 1
INCB018424 in Patients With Advanced Hematologic Malignancies Start of enrollment: 2008 May 12
Completed
Phase 2
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2008 Oct 01
Completed
Phase 2
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 2
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes Start of enrollment: 2009 Sep 01
Completed
Phase 1
Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome Start of enrollment: 2011 Jan 01
Completed
Phase 1, Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Start of enrollment: 2011 Oct 05
Recruiting
Phase 2
Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients Start of enrollment: 2012 Oct 01
Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML) Start of enrollment: 2013 Feb 05
Completed
Phase 2
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia Start of enrollment: 2013 Apr 30
Active, not recruiting
Phase 2
Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2013 Dec 17
Terminated
Phase 1
MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy Start of enrollment: 2014 Aug 27
Terminated
Phase 1, Phase 2
Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation Start of enrollment: 2015 Feb 06
Completed
Phase 2
Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia Start of enrollment: 2015 Feb 12
Completed
Phase 1, Phase 2
A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders Start of enrollment: 2016 Dec 02
Completed
Phase 1
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Start of enrollment: 2018 Jun 26
Active, not recruiting
Phase 1, Phase 2
Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2021 Feb 22
Recruiting
Phase 2
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Start of enrollment: 2021 Jul 08
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine Start of enrollment: 2023 Oct 09
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

333 citations
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Naval Daver, Guillermo Garcia-Manero, Sreyashi Basu, Prajwal Boddu, Mansour Alfayez
Cancer Discovery. 2019-03-01
41 citations
Hematologic malignancies and Li-Fraumeni syndrome.
Mahesh Swaminathan, Sarah A. Bannon, Mark J. Routbort, Kiran Naqvi, Tapan M. Kadia
Cold Spring Harbor Molecular Case Studies. 2019-02-01
163 citations
Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines
Daniel A. Pollyea, Dale L. Bixby, Alexander E. Perl, Vijaya Raj Bhatt, Jessica K. Altman
Journal of the National Comprehensive Cancer Network. 2021-01-06

Abstracts/Posters

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration t...
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphob...
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA ...
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly D...
Farhad Ravandi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

AML: Expert Guidance on Current Standards and New Directions in Patient Care
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia.
2019 ASCO Annual Meeting - 6/1/2019
Moving Toward Precision Therapy for Patients with AML: Clinical Challenges and Future Directions
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

Clinical Challenges: Treating TP53-Mutated Acute Myeloid LeukemiaMay 16th, 2022
Clinical Challenges: Maintenance Therapy for AMLMay 10th, 2022
MD Anderson Research Highlights for September 21, 2023September 22nd, 2023

Hospital Affiliations

University of Texas M.D. Anderson Cancer CenterHouston, Texas

FarhadRavandi-KashaniMD

Dr. Ravandi-Kashani is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.